Participation is open to worldwide institutions.
    Read More
    Since 1998, an Annual Meeting of the IELSG investigators has been regularly held.
    Read More
    The IELSG Newsletter informs about studies, meetings and other research activities.
    Read More
    The results are presented to major congresses and published into peer-reviewed journals.
    Read More

Fighting cancer through research. You can support us by making a donation, however large or small.

Support Us


  • IELSG Studies presented during 17-ICML

    Oral presentations
    IELSG37 – A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy
    IELSG39 – The IELSG39 trial: efficacy of first-line chlamydia psitaci eradication with a six-month regimen of doxycycline in patients with stage-I MALT lymphoma of ocular adnexae
    IELSG43 – Consolidative HCT-ASCT is superior to non-myeloablative chemo-immuotherapy in newly-diagnosed PCNSL – Updated results of the randomized phase IIMATRix/IELSG43 trial
    IELSG47 – Rituximab and ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IESLG47/MALIBU phase II study

    Poster presentation
    IELSG35 – Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group

  • IELSG Annual Meeting 2024

    The next Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 8-9, 2024 in Stresa (Italy) at Hotel La Palma.

    More information will follow soon.


  • IELSG50
    IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy Participants required: 30… Read more: IELSG50
  • IELSG44
    IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s):… Read more: IELSG44
  • IELSG45 Study
    Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial)